Browsing Tag
Volt PFA System
2 posts
Abbott (NYSE: ABT) showcases four HRS 2026 trials as cardiac rhythm market competition intensifies
Abbott has fresh arrhythmia data, but its stock sits near yearly lows. Can cardiac innovation reset investor confidence?
Abbott’s Volt PFA system delivers strong 12-month AFib outcomes, heart rhythm society 2025 data reveal
Explore how Abbott’s Volt™ PFA System is redefining AFib treatment with groundbreaking 12-month results — see why it’s a game-changer in cardiac care.